100927-09-1

Basic information

• Product Name: Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI);(R)-tert-butyl 1-cyanoethylcarbamate;tert-butyl N-[(1R)-1-cyanoethyl]carbaMate;(R)-(alpha-Cyano-alpha-methylmethyl)carbamic acid tert-butyl ester;N-[(1R)-1-Cyanoethyl]carbamic acid tert-butyl ester
• CAS NO: 100927-09-1
• Molecular Formula: C8H14N2O2
• Molecular Weight: 170.20896
• Product Categories: N-BOC
• Mol File: 100927-09-1.mol

Chemical Properties

• Boiling Point: 277℃
• Flash Point: 121℃
• Appearance: /
• Density: 1.021
• PKA: 10.14±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI)(100927-09-1)
• EPA Substance Registry System: Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI)(100927-09-1)

Safety Data

• Hazardous Substances Data: 100927-09-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent and intermediate in the production of pharmaceuticals. It plays a crucial role in the synthesis of various drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI) is also utilized in the production of agrochemicals, specifically in the synthesis of pesticides and other agricultural chemicals. Its use in this industry helps to develop more effective and safer products for crop protection and management.
Used as an Intermediate in Organic Synthesis:
Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI) is employed as an intermediate in the synthesis of other organic compounds. Its unique chemical properties make it a valuable building block for creating a wide range of organic molecules, including specialty chemicals and advanced materials.
It is important to handle Carbamic acid, [(1R)-1-cyanoethyl]-, 1,1-dimethylethyl ester (9CI) with care and follow appropriate safety protocols due to its potential hazards if not handled properly.

Upstream product

• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 365441-85-6 N-(tert-butoxycarbonyl)-1-tosyleth-1-ylamine 
• 78981-25-6 N-(tert-butoxycarbonyl)-D-alanine amide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3744-87-4 Boc-(R)-Ala 

Downstream Products

• 657424-10-7 C₈H₁₇N₃O₃ 

Relevant articles and documents

Synthesis of 3,5-disubstituted 1,2,4-oxadiazoles as peptidomimetic building blocks

Twelve new 1,2,4-oxadiazole based compounds have been synthesized. Their structures contain a protected amine and a carboxyl or an ester group, and thus serve as potential peptidomimetic building blocks. The synthetic route is simple and mild conditions are used so that the chirality of the starting amino acids is retained.

Phase transfer catalyzed enantioselective strecker reactions of α-amido sulfones with cyanohydrins

A study into the use of a chiral phase-transfer catalyst in conjunction with acetone cyanohydrin to effect the enantioselective formation of α-amino nitriles from α-amido sulfones is described. This novel catalytic asymmetric Strecker reaction is analyzed

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Total syntheses of bacillamide C and neobacillamide A; Revision of their absolute configurations

The enantiospecific syntheses of both enantiomers of bacillamide C and neobacillamide A are described, along with the measurement of their optical activities, leading to the revision of the proposed absolute configurations of these natural products.

4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors

Sphingosine 1-phosphate (S1P), a potent phospholipid growth and trophic factor, is synthesized in vivo by two sphingosine kinases. Thus these kinases have been proposed as important drug targets for treatment of hyperproliferative diseases and inflammation. We report here a new class of amidine-based sphingosine analogues that are competitive inhibitors of sphingosine kinases exhibiting varying degrees of enzyme selectivity. These inhibitors display KI values in the submicromolar range for both sphingosine kinases and, in cultured vascular smooth muscle cells, decrease S1P levels and initiate growth arrest.

NEW COMPOUNDS

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Solid phase nitrile synthesis

A nitrile compound is prepared by treating a solid supported amide to dehydrate it and cleave it from the support in one operation. The preparation involves acetylation of the amide compound in the presence of a base at a temperature of less than 100° C.